JOURNAL ARTICLE

Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial

Keywords:
Medicine Regorafenib Internal medicine Clinical endpoint Hazard ratio GiST Randomization Placebo Gastroenterology Randomized controlled trial Response Evaluation Criteria in Solid Tumors Sunitinib Surrogate endpoint Progression-free survival Phases of clinical research Surgery Confidence interval Cancer Clinical trial Colorectal cancer Pathology Chemotherapy Stromal cell

Metrics

0
Cited By
0.00
FWCI (Field Weighted Citation Impact)
0
Refs
0.43
Citation Normalized Percentile
Is in top 1%
Is in top 10%

Topics

Gastrointestinal Tumor Research and Treatment
Health Sciences →  Medicine →  Gastroenterology
Gastric Cancer Management and Outcomes
Health Sciences →  Medicine →  Pulmonary and Respiratory Medicine
Gastrointestinal disorders and treatments
Health Sciences →  Medicine →  Surgery

Related Documents

© 2026 ScienceGate Book Chapters — All rights reserved.